Mouna Lazrek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mouna Lazrek has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Enagnon Kazali Alidjinou
Laboratoire de Virologie ULR3610 Univ Lille et CHU de Lille Lille France
4 shared publications A. Dewilde
CHRU de LILLE / Univ. Lille (2)
3 shared publications- Didier Hober
Laboratoire de Virologie ULR3610 Univ Lille et CHU de Lille Lille France
3 shared publications - Ilka Engelmann
INSERM, Pathogenesis and Control of Chronic and Emerging Infections, PCCEI U1058 Montpellier University Montpellier France
3 shared publications - Céline Goeminne
CHU Lille, Unité de Transplantation et Assistance Cardiaque, Lille, France
2 shared publications - Fanny Vuotto
Service de Maladies Infectieuses, Centre Hospitalier Universitaire de Lille , F-59000 Lille
2 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 31 (44) , 2600054
Seroprevalence of EV-A71 and EV-D68 antibodies in the paediatric and adolescent population, France, 2023 to 2025
BACKGROUND: Enteroviruses (EV)-A71 and EV-D68 are potentially associated with severe clinical conditions, especially in infants and young children. Population susceptibility to these viruses is unknown in France. AIM: We sought to estimate seroprevalence of EV-A71 and EV-D68 neutralising antibodies (nAbs) among children and adolescents living in France. METHODS: A stratified sampling approach based on sex, age and geographical area of residence was applied to obtain sera for routine diagnostic from ˂ 18-year-olds in metropolitan France. A total of 501 serum samples collected between 2023 and 2025 from 0–17-year-olds were included in the investigation. Neutralising activity was tested against EV-A71 sub-genogroup C1 and EV-D68 subclade B3 strains isolated in 2016, allowing to determine seropositivity and nAb titre. Data were analysed overall, by sex, age group and geographical area. RESULTS: For EV-A71, the overall estimated seroprevalence was 43.7% (95% CI: 39.3−48.2) while for EV-D68 this reached 96.0% (95% CI: 93.9–97.5). No differences according to sex were observed. Unlike EV-D68, EV-A71 seropositivity rate varied significantly by age group (p = 0.002) and area of residence (p < 0.001). Notably, 23 of 25 children aged ˂ 1 year lacked EV-A71 protective antibodies. Concerning nAb titres, significant differences occurred across age groups both for EV-A71 (p = 0.004) and EV-D68 (p < 0.001). The nAb titres appeared as highest in 1 to under-2-year-olds for EV-A71 and 0 to under-1-year-olds for EV-D68. CONCLUSION: This seroprevalence study in France reveals a high proportion of newborns and infants susceptible to EV-A71 at potential risk of severe disease, contrasting with the high level of immunity against EV-D68 across all paediatric age groups.
- 5 November 2026
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 31 (44) , 2600054
Open AccessSeroprevalence of EV-A71 and EV-D68 antibodies in the paediatric and adolescent population, France, 2023 to 2025
BACKGROUND: Enteroviruses (EV)-A71 and EV-D68 are potentially associated with severe clinical conditions, especially in infants and young children. Population susceptibility to these viruses is unknown in France. AIM: We sought to estimate seroprevalence of EV-A71 and EV-D68 neutralising antibodies (nAbs) among children and adolescents living in France. METHODS: A stratified sampling approach based on sex, age and geographical area of residence was applied to obtain sera for routine diagnostic from ˂ 18-year-olds in metropolitan France. A total of 501 serum samples collected between 2023 and 2025 from 0–17-year-olds were included in the investigation. Neutralising activity was tested against EV-A71 sub-genogroup C1 and EV-D68 subclade B3 strains isolated in 2016, allowing to determine seropositivity and nAb titre. Data were analysed overall, by sex, age group and geographical area. RESULTS: For EV-A71, the overall estimated seroprevalence was 43.7% (95% CI: 39.3−48.2) while for EV-D68 this reached 96.0% (95% CI: 93.9–97.5). No differences according to sex were observed. Unlike EV-D68, EV-A71 seropositivity rate varied significantly by age group (p = 0.002) and area of residence (p < 0.001). Notably, 23 of 25 children aged ˂ 1 year lacked EV-A71 protective antibodies. Concerning nAb titres, significant differences occurred across age groups both for EV-A71 (p = 0.004) and EV-D68 (p < 0.001). The nAb titres appeared as highest in 1 to under-2-year-olds for EV-A71 and 0 to under-1-year-olds for EV-D68. CONCLUSION: This seroprevalence study in France reveals a high proportion of newborns and infants susceptible to EV-A71 at potential risk of severe disease, contrasting with the high level of immunity against EV-D68 across all paediatric age groups.
- 29 August 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (12) , e15109
Reliability of QuantiFERON®‐CMV in predicting CMV recurrence in heart transplant recipients: A single‐center retrospective study
Background: Recurrence after Cytomegalovirus (CMV) infection in heart transplant recipients is difficult to predict, in spite of its high incidence. Secondary prophylaxis could reduce this burden; however, its duration remains unestablished. We evaluated the QuantiFERON®‐CMV test to see if it could predict CMV recurrence and help optimize the duration of secondary prophylaxis.Methods: This observational retrospective single center study included all heart transplant recipients who developed CMV infection between 2019 and 2021, with the CD8+ T‐cell‐mediated CMV immunity QuantiFERON®‐CMV test assessed at the time of (val)ganciclovir curative treatment completion. The main outcomes were CMV recurrence and duration of secondary prophylaxis. Secondary outcomes included immunosuppressive regimen, rejection, lymphocyte count, CMV viral load, infection type, and duration as possible confounding factors for recurrence.Results: Among the 15 patients included, five (33%) experienced recurrence, of whom three (60%) had a positive QuantiFERON®‐CMV test. The duration of secondary prophylaxis was similar regardless of QF‐CMV positivity. No confounding factor was significantly associated with CMV recurrence; however, it occurred in only 1/7 (14%) of the patients receiving an everolimus‐containing immunosuppressive regimen.Conclusion: In the population of heart transplant recipients, most of whom received ATG‐based induction, the QuantiFERON®‐CMV assay may not accurately predict CMV recurrence and would have not helped refining the duration of secondary prophylaxis in our patients. Other cell‐mediated immunity tests and strategies in this specific population, including everolimus‐containing regimens, may help predict and manage CMV recurrence.
- 29 August 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (12) , e15109
Reliability of QuantiFERON®‐CMV in predicting CMV recurrence in heart transplant recipients: A single‐center retrospective study
Background: Recurrence after Cytomegalovirus (CMV) infection in heart transplant recipients is difficult to predict, in spite of its high incidence. Secondary prophylaxis could reduce this burden; however, its duration remains unestablished. We evaluated the QuantiFERON®‐CMV test to see if it could predict CMV recurrence and help optimize the duration of secondary prophylaxis.Methods: This observational retrospective single center study included all heart transplant recipients who developed CMV infection between 2019 and 2021, with the CD8+ T‐cell‐mediated CMV immunity QuantiFERON®‐CMV test assessed at the time of (val)ganciclovir curative treatment completion. The main outcomes were CMV recurrence and duration of secondary prophylaxis. Secondary outcomes included immunosuppressive regimen, rejection, lymphocyte count, CMV viral load, infection type, and duration as possible confounding factors for recurrence.Results: Among the 15 patients included, five (33%) experienced recurrence, of whom three (60%) had a positive QuantiFERON®‐CMV test. The duration of secondary prophylaxis was similar regardless of QF‐CMV positivity. No confounding factor was significantly associated with CMV recurrence; however, it occurred in only 1/7 (14%) of the patients receiving an everolimus‐containing immunosuppressive regimen.Conclusion: In the population of heart transplant recipients, most of whom received ATG‐based induction, the QuantiFERON®‐CMV assay may not accurately predict CMV recurrence and would have not helped refining the duration of secondary prophylaxis in our patients. Other cell‐mediated immunity tests and strategies in this specific population, including everolimus‐containing regimens, may help predict and manage CMV recurrence.
- 2 October 2021
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 102 (1) , 115565
SARS-CoV-2 infection long time after full vaccination is related to a lack of neutralizing antibodies
- 2 October 2021
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 102 (1) , 115565
SARS-CoV-2 infection long time after full vaccination is related to a lack of neutralizing antibodies
- Open Access
- 12 May 2021
- Published by Radcliffe Medical Media Ltd in Cardiac Failure Review
- Vol. 7
Fatal Enterovirus-related Myocarditis in a Patient with Devic’s Syndrome Treated with Rituximab
Enteroviruses are a frequent source of infection and among the most common central nervous system viral pathogens. Enteroviruses – in particular, the Coxsackie B viruses – are a known cause of myocarditis. Rituximab is a genetically engineered chimeric anti-CD20 monoclonal antibody. Many reports in the literature suggest a higher risk of infection following repeated rituximab therapy, including viral infection. However, observations of enterovirus-related myocarditis in the context of rituximab treatment are scarce. The authors describe the case of a patient with neuromyelitis optica spectrum disorder who developed severe and fatal enterovirus-related myocarditis after rituximab therapy with a difficult differential diagnosis of autoimmune or giant-cell myocarditis. This case highlights the importance of complete diagnostic workup in difficult cases of myocarditis, including endomyocardial biopsies.
- 12 May 2021
- Published by Radcliffe Medical Media Ltd in Cardiac Failure Review
- Vol. 7
Open AccessFatal Enterovirus-related Myocarditis in a Patient with Devic’s Syndrome Treated with Rituximab
Enteroviruses are a frequent source of infection and among the most common central nervous system viral pathogens. Enteroviruses – in particular, the Coxsackie B viruses – are a known cause of myocarditis. Rituximab is a genetically engineered chimeric anti-CD20 monoclonal antibody. Many reports in the literature suggest a higher risk of infection following repeated rituximab therapy, including viral infection. However, observations of enterovirus-related myocarditis in the context of rituximab treatment are scarce. The authors describe the case of a patient with neuromyelitis optica spectrum disorder who developed severe and fatal enterovirus-related myocarditis after rituximab therapy with a difficult differential diagnosis of autoimmune or giant-cell myocarditis. This case highlights the importance of complete diagnostic workup in difficult cases of myocarditis, including endomyocardial biopsies.
- 1 June 2016
- Published by Elsevier in Medecine Et Maladies Infectieuses
- Vol. 46 (4) , 128-129
VIRO-03 - Cas d’entérocolite nécrosante associés à une infection nosocomiale à entérovirus dans une unité de néonatologie
- 1 June 2016
- Published by Elsevier in Medecine Et Maladies Infectieuses
- Vol. 46 (4) , 128-129
VIRO-03 - Cas d’entérocolite nécrosante associés à une infection nosocomiale à entérovirus dans une unité de néonatologie
- 1 June 2016
- Published by Elsevier in Medecine Et Maladies Infectieuses
- Vol. 46 (4) , 128
VIRO-02 - Infections néonatales à Entérovirus et Parechovirus
- 1 June 2016
- Published by Elsevier in Medecine Et Maladies Infectieuses
- Vol. 46 (4) , 128
VIRO-02 - Infections néonatales à Entérovirus et Parechovirus
- 1 February 2016
- Published by Elsevier in Journal of Clinical Virology
- Vol. 75, 60-63
A patient with fever, abdominal pain and bicytopenia: Trouble once again with these IgM antibodies!
- 1 February 2016
- Published by Elsevier in Journal of Clinical Virology
- Vol. 75, 60-63
A patient with fever, abdominal pain and bicytopenia: Trouble once again with these IgM antibodies!